NEW YORK, March 30, 2017 /PRNewswire/ --
In today's pre-market research, Stock-Callers.com directs investors' attention to Agenus Inc. (NASDAQ: AGEN), Intrexon Corp. (NYSE: XON), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), and Concordia International Corp. (NASDAQ: CXRX). According an article on Barron's, Credit Suisse upgraded its rating on the Pharmaceuticals/Biotechnology sector to "Overweight" from "Market Weight" on Tuesday, March 21st, 2017. These stocks research reports can be downloaded now by simply registering for free at:
Lexington, Massachusetts headquartered Agenus Inc.'s stock finished Wednesday's session flat at $3.92 with a total trading volume of 1.01 million shares. The Company's shares are trading below their 50-day moving average by 2.60%. Shares of the Company, which focuses on the discovery and development of therapies that engage the body's immune system for patients suffering with cancer, have a Relative Strength Index (RSI) of 48.08.
On March 24th, 2017, Agenus announced its participation on March 30th, 2017 at the following conferences: The 7th Annual William Blair and Maidstone Life Sciences conference "Cancer Immunotherapy Conference" at the Apella, Event Space Alexandria Center in New York, NY; and the Jefferies Immuno-Oncology Summit at the Boston Harbor Hotel in Boston, MA. Your complete research report on AGEN can be retrieved for free at:
Shares in Germantown, Maryland-based Intrexon Corp. rose 1.40%, ending yesterday's session at $20.23 with a total trading volume of 1.10 million shares. The stock is trading 7.66% below its 50-day moving average. Shares of the Company, which operates in the synthetic biology field in the US, have an RSI of 44.66.
On March 10th, 2017, Intrexon announced the formation of Precigen, Inc., a wholly-owned subsidiary of the former, as part of an ongoing evaluation of structural alternatives concerning its business in healthcare. Intrexon currently intends to consolidate all health-related assets under this new corporate entity as it considers potential strategic options to enhance shareholder value. A free report on XON is just a click away at:
On Wednesday, New York-based Progenics Pharmaceuticals Inc.'s stock saw a decline of 1.16%, to close the day at $10.23. A total volume of 1.21 million shares was traded. The Company's shares have advanced 10.59% in the previous three months and 18.40% on an YTD basis. The stock is trading 0.35% and 35.92% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Progenics Pharmaceuticals, which develops medicines and other technologies to target and treat cancer in the US and internationally, have an RSI of 43.89.
On March 24th, 2017, Progenics Pharmaceuticals announced the publication of previously reported results from the Phase-2 study of 1404 in the online edition of the Journal of Nuclear Medicine. 1404 is a PSMA-targeted small molecule SPECT/CT imaging agent that is designed to visualize prostate cancer. Sign up for your complimentary research report on PGNX at:
Shares in Oakville, Canada headquartered Concordia International Corp. ended the day 0.62% higher at $1.63 with a total trading volume of 594,054 shares. The stock is trading below its 50-day moving average by 25.07%. Shares of the Company, which owns a portfolio of branded and generic prescription products in the US and internationally, have an RSI of 39.15.
On March 15th, 2017, Concordia International announced its financial and operational results for the three and twelve months ended December 31st, 2016. For Q4 2016, consolidated revenue was $170.4 million and adjusted EBITDA was $80.5 million. For the year, consolidated revenue was $816.2 million; GAAP net loss from continuing operations was $1,314.1 million; and adjusted EBITDA was $468.1 million. Register for free on Stock-Callers.com and download the latest research report on CXRX at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA